Nexelis
Trending Articles
Related Content
Ingredients
Why the production of bispecific antibodies depends on early stage product characterisation
Chloe Ackaert, Senior Scientist, and Sofie Pattijn, Chief Technology Officer and founder, ImmunXperts a Nexelis group company, explain how early development studies to evaluate functionality and immunogenicity help to derisk the manufacture of bispecific antibodies